North america in vitro diagnostics market outlook to 2018

http://www.salisonline.org Tel: +1-518-618-1030 sales@researchmoz.com

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry
Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry,
Infectious Immunology and Microbiology Culture

Summary

GlobalData’s new report, North America In Vitro Diagnostics Market Outlook to 2018- Clinical
Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious
Immunology and Microbiology Culture provides key market data on the North America In Vitro
Diagnostics market - Canada and United States. The report provides value (USD million) data for all the
market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno
Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares
and distribution shares data for each of the aforementioned market categories. The report is
supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

- Countries covered include Canada and United States.
- Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry,
Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture.
- Annualized market revenues (USD million) data for each of the market categories in each of the
country. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories and countries.
- Global corporate-level profiles of key companies operating within the North America In Vitro
Diagnostics market..
- Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd.,
Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong
growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the North America In Vitro
Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register
strong growth in the near future.


- What are the key distribution channels and what’s the most preferred mode of product distribution -
Identify, understand and capitalize

BUY NOW

Table of Contents

1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 15
2 Introduction 16
2.1 What is This Report About? 16
3 In Vitro Diagnostics in North America 17
3.1 In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 17
3.2 In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 18
3.3 In Vitro Diagnostics, North America, Company share (2010-2011) 26
4 In Vitro Diagnostics In United States 28
4.1 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 28
4.2 In Vitro Diagnostics, United States, Distribution Share (2010-2011) 34
4.3 In Vitro Diagnostics, United States, Company Share (2010-2011) 38
5 In Vitro Diagnostics In Canada 51
5.1 In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 51
5.2 In Vitro Diagnostics, Canada, Distribution Share (2010-2011) 57
5.3 Clinical Chemistry Distribution Share (2010-2011) 57
5.4 In Vitro Diagnostics, Canada, Company Share (2010-2011) 61
5.5 Microbiology Culture, Canada, Company Share (2010-2011) 75
6 Overview of Key Companies in North America In Vitro Diagnostics 77
6.1 Siemens Healthcare 77
6.2 Abbott Laboratories 78
6.3 F. Hoffmann-La Roche Ltd. 79
6.4 Beckman Coulter, Inc. 80
6.5 Ortho-Clinical Diagnostics Inc. 81
6.6 Alere Inc. 82
6.7 bioMerieux S.A. 83
6.8 Becton, Dickinson and Company 83
6.9 Bio-Rad Laboratories, Inc. 84
6.10 Sysmex Corporation 84


6.11 Qiagen N.V. 85
6.12 Gen-Probe Incorporated 85
6.13 DiaSorin S.p.A 86
6.14 Immucor, Inc. 86
6.15 Thermo Fisher Scientific Inc. 87
6.16 Hologic, Inc. 87
6.17 Cepheid 88
6.18 PerkinElmer, Inc. 88
6.19 Grifols, S.A. 89
6.20 ELITech Group 89
6.21 Life Technologies Corporation 90
6.22 Horiba, Ltd. 90
6.23 Biomedica Diagnostics Inc. 91
6.24 Diagnostica Stago, Inc. 91
6.25 OraSure Technologies, Inc. 91
7 North America Market Pipeline Products 92
7.1 Clinical Chemisty Market Pipeline Products 92
7.2 Immuno Chemistry Market Pipeline Products 99
7.3 Haematology Market Pipeline Products 110
7.4 Infectious Immunology Market Pipeline Products 112
7.5 Microbiology Culture Market Pipeline Products 119
7.6 Histology And Cytology Market Pipeline Products 121
7.7 Genetic Testing Market Pipeline Products 122
8 Financial Deals Landscape 127
8.1 Acquisition 127
8.2 Partnerships 177
9 Recent Developments 442
9.1 Strategy And Business Planning 442
9.2 Research And Development 474
9.3 Legal and Regulatory 482
9.4 Government and Public Interest 511
9.5 Product News 572
10 Appendix 734
10.1 Definitions of Markets Covered in the Report 735
10.2 Research Methodology 746
10.3 Secondary Research 746
10.4 Primary Research 747
10.5 Models 747
10.6 Forecasts 748
10.7 Expert Panels 748
10.8 GlobalData Consulting 748
10.9 Currency Conversion 749


10.10 Contact Us 749
10.11 Disclaimer 7491.1 List of Tables
Table 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m),USD Constant, 2004-
2018 44
Table 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018
46
Table 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2004-2018 48
Table 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Historic,
2004-2011 50
Table 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 52
Table 6: In Vitro Diagnostics, North America, Company share by Revenue ($m), USD Constant,
2010-2011 54
Table 7: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018
56
Table 8: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic,
2004-2011 58
Table 9: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 60
Table 10: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 61
Table 11: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Constant,
2010-2011 61
Table 12: Haematology, United States, Distribution Share by Revenue ($m), USD Constant,
2010-2011 62
Table 13: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 62
Table 14: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 63
Table 15: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 63
Table 16: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 64
Table 17: In Vitro Diagnostics, United States, Company Share by Revenue ($m), USD Constant,
2010-2011 66
Table 18: Clinical Chemistry, United States, Company Share by Revenue ($m), USD Constant,
2010-2011 67
Table 19: Genetic Testing, United States, Company Share by Revenue ($m), USD Constant,
2010-2011 69
Table 20: Haematology, United States, Company Share by Revenue ($m), USD Constant, 2010-
2011 71
Table 21: Immuno Chemistry, United States, Company Share by Revenue ($m), USD Constant,


2010-2011 73
Table 22: Infectious Immunology, United States, Company Share by Revenue ($m), USD
Constant, 2010-2011 75
Table 23: Microbiology Culture, United States, Company Share by Revenue ($m), USD
Constant, 2010-2011 77
Table 24: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 79
Table 25: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Historic, 2004-
2011 81
Table 26: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 83
Table 27: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Constant,
2010-2011 84
Table 28: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 84
Table 29: Haematology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 85
Table 30: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 85
Table 31: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Constant,
2010-2011 86
Table 32: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Constant,
2010-2011 86
Table 33: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Constant,
2010-2011 87
Table 34: In Vitro Diagnostics, Canada, Company Share by Revenue ($m), USD Constant, 2010-
2011 89
Table 35: Clinical Chemistry, Canada, Company Share by Revenue ($m), USD Constant, 2010-
2011 91
Table 36: Genetic Testing, Canada, Company Share by Revenue ($m), USD Constant, 2010-
2011 93
Table 37: Haematology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
95
Table 38: Histology And Cytology, Canada, Company Share by Revenue ($m), USD Constant,
2010-2011 97
Table 39: Immuno Chemistry, Canada, Company Share by Revenue ($m), USD Constant, 2010-
2011 99
Table 40: Infectious Immunology, Canada, Company Share by Revenue ($m), USD Constant,
2010-2011 101
Table 41: Microbiology Culture, Canada, Company Share by Revenue ($m), USD Constant,
2010-2011 103
Table 42: Clinical Chemisty Market Pipeline Products 119
Table 43: Immuno Chemistry Market Pipeline Products 126


Table 44: Haematology Market Pipeline Products 137
Table 45: Infectious Immunology Market Pipeline Products 139
Table 46: Microbiology Culture Market Pipeline Products 146
Table 47: Histology And Cytology Market Pipeline Products 148
Table 48: Genetic Testing Market Pipeline Products 149
Table 49: SQI Diagnostics Plans For Sale Of The Company 154
Table 50: Sparton Completes Acquisition Of Onyx EMS, Contract Manufacturing Services
Provider, For $43 Million 155
Table 51: ERBA Diagnostics Acquires Drew Scientific, Maker Of Analytical Instruments And
Reagents, For $6.5 Million 157
Table 52: Measurement Specialties Acquires Cambridge Technologies And Resistance
Temperature Detector Company For $18.8 Million 159
Table 53: Atossa Genetics Acquires Acueity Healthcare, Diagnostic Device Provider 160
Table 54: AccelPath Acquires DigiPath Solutions For $2.4 Million 161
Table 55: Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test
Maker, For $324 Million 162
Table 56: Charles River Labs Acquires Accugenix, Provider Of Microbe Identification Services,
For $17 Million 164
Table 57: Leica Biosystems Completes Acquisition Of Aperio Technologies 166
Table 58: Metabolon Acquires Lipomics Technologies, Diagnostics Company 169
Table 59: Waters Acquires Blue Reference, Maker Of Application Scientific Databases, For $14
Million 171
Table 60: Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 172
Table 61: Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant
Diagnostics Company, For $925 Million 173
Table 62: Life Technologies Acquires Navigenics 175
Table 63: Genova Diagnostics Acquires Metametrix, Clinical Laboratory 177
Table 64: 23andMe Acquires CureTogether, Healthcare IT Company 178
Table 65: Luminex To Acquire GenturaDx, Molecular Diagnostics Company, For $50 Million
179
Table 66: Systagenix Acquires O2 Insights 181
Table 67: Maxxam Analytics Acquires Becquerel Labs, Provider Of Testing Services 182
Table 68: LabCorp Completes Acquisition Of Medtox Scientific For $241 Million 183
Table 69: Flagship Biosciences Acquires Ihctech, Provider Of Research Immunohistochemistry
And Histology Services 185
Table 70: Halo Healthcare Acquires NeoMatrix, Maker Of Diagnostic Equipments 186
Table 71: Pacepartners To Acquire Vivione BioSciences 187
Table 72: Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test
Solutions 188
Table 73: Hologic Completes Acquisition Of Gen-Probe For $3.7 Billion 189
Table 74: Haemonetics To Acquire Hemerus Medical, Provider Of Leukoreduction
Technologies, For $27 Million 192


Table 75: IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From
GE Healthcare Bio-Sciences 194
Table 76: Beckman Coulter Acquires Blue Ocean Biomedical From Npe Systems 195
Table 77: Abcam Completes Acquisition Of Epitomics, Rabbit Monoclonal Antibodies Provider,
For $155 Million 196
Table 78: Ontario Genomics Institute Acquires Minority Stake In RNA Diagnostics For $0.1
Million 198
Table 79: PhotoVoltaic Solar Cells Acquires MetaStat, Life Science Company 199
Table 80: Alere To Acquire eScreen, Provider Of Health Testing Products And Services, For Up
To $340 Million 200
Table 81: Bode Technology Group Acquires Provider Of DNA Analysis Testing Services,
Chromosomal Labs 202
Table 82: Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 203
Table 83: Multiple Myeloma Research Foundation Enters Into Co-Development Agreement
With GenoSpace 204
Table 84: Empire Genomics Enters Into Licensing Agreement With Emory University For
Genomic Biomarkers 205
Table 85: NanoPass Technologies Enters Into Licensing Agreement With Janssen Pharma For
MicronJet 206
Table 86: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For
Transcreener Epigen Methyltransferase Assay 207
Table 87: BioView Enters Into Agreement With Abbott To Develop Automated Cancer
Screening System 209
Table 88: Institute of Microelectronics Enters Into Co-Development Agreement With SFC
Fluidics 210
Table 89: HTG Molecular Diagnostics Enters Into Licensing Agreement With Centre of
Excellence for Prevention of Organ Failure For COPD Prognostic Test 211
Table 90: Pressure BioSciences Enters Into Co-Marketing Agreement With Constant Systems
For High Pressure Technologies 212
Table 91: CML HealthCare Enters Into Licensing Agreement With Mitomics For Prostate
Cancer Test 214
Table 92: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology
215
Table 93: DioGenix Enters Into Agreement With Fast Forward To Develop New Blood Test For
Multiple Sclerosis 217
Table 94: GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount
Sinai School of Medicine 219
Table 95: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery
221
Table 96: CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests
222
Table 97: Clinical Genomics Enters Into Licensing Agreement With Quest Diagnostics For


Colon Cancer Markers 223
Table 98: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo
Blood Chemistry System 224
Table 99: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 226
Table 100: Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors
For Archimedes Particle Metrology System 227
Table 101: Exosome Diagnostics Enters Into Co-Development Agreement With Promega For
Urine Clinical Sample Concentrator Kit 228
Table 102: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ
229
Table 103: Ezose Enters Into Co-Development Agreement With Fast Forward For Multiple
Sclerosis Biomarkers 230
Table 104: BioDot Enters Into Co-Marketing Agreement With JOT Automation 231
Table 105: Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology
232
Table 106: LifeTech Scientific, DiNova Venture Partners, Themes Investment Partners And
Broncus Technologies Partner To Form Broncus Medical 233
Table 107: Van Andel Institute Enters Into Co-Development Agreement With Emory University
235
Table 108: Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early
Embryo Viability Assessment Test 236
Table 109: PGXL Labs Enters Into Joint Venture Agreement With Essential Molecular Testing
237
Table 110: Broad Institute Enters Into Distribution Agreement With Appistry For Genome
Analysis Toolkit 238
Table 111: Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 239
Table 112: Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays
240
Table 113: Bruker Enters Into An Agreement With Nextval For High-throughput Screening
Technology 241
Table 114: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New
Oncology Assays 242
Table 115: RainDance Technologies Enters Into Co-Development Agreement With Integrated
DNA Technologies For Digital PCR 243
Table 116: Amarantus BioSciences Enters Into Option For Licensing Agreement With Memory
Dx For LymPro Blood Test 245
Table 117: Iverson Genetic Diagnostics Enters Into Licensing Agreement With Johns Hopkins
University School For Molecular Diagnostic Tests 246
Table 118: Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics
For miRview mets2 Assays 247
Table 119: Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core


Mitomic Test 248
Table 120: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis
Dx 250
Table 121: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And
Diagnostic Discovery 251
Table 122: Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 252
Table 123: Augurex Life Sciences Enters Into Licensing Agreement With Quest Diagnostics For
14-3-3n Biomarker 253
Table 124: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital
Microscopy Hematology Solutions 254
Table 125: Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies
For Diagnostic Solutions 256
Table 126: Med BioGene Amends Licensing Agreement With Precision Therapeutics For
LungExpress Dx Test 258
Table 127: Genia Technologies Enters Into Co-Development Agreement With Columbia
University And Harvard University 260
Table 128: NextBio Enters Into Agreement With Winship Cancer Institute of Emory University
For Myeloma Biomarkers 262
Table 129: Proof Centre Enters Into Co-Development Agreement With AllerGen For Allergy
Biomarkers 263
Table 130: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon
Biotechnology 264
Table 131: Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For
MASCT System 265
Table 132: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For Maverick
Detection Platform 266
Table 133: CML HealthCare Enters Into Agreement With MaRS Innovation 267
Table 134: Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion
Diagnostics Development 268
Table 135: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular
Discovery 269
Table 136: Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics
270
Table 137: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's
Hospital For Mesothelioma Test 271
Table 138: Illumina Enters Into Technology Integration Agreement With Partners HealthCare
System 272
Table 139: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For
Protein Array Products 274
Table 140: ImaginAb Enters Into Co-Development Agreement With MacroGenics 275
Table 141: BellBrook Labs Enters Into Co-Development Agreement With Reaction Biology 276
Table 142: GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute


For GOBIOM Database 277
Table 143: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 278
Table 144: Perkinelmer Enters Into Co-Development Agreement With Massachusetts General
Hospital 279
Table 145: Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 281
Table 146: Axela Enters Into Co-Marketing Agreement With OvaGene Oncology 282
Table 147: University of Michigan Enters Into Joint Venture Agreement With International
Genomics Consortium 283
Table 148: Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers
284
Table 149: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 285
Table 150: Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology
286
Table 151: Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers
Squibb 287
Table 152: Epistem Enters Into Distribution Agreement With Becton Dickinson For
Mycobacterium TB Test 288
Table 153: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 289
Table 154: Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched
DNA Technology 290
Table 155: Molecular Targeting Technologies Enters Into Licensing Agreement With Medical
College of Wisconsin For 99mTc-HYNIC-Duramycin 291
Table 156: Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics
For miRview mets2 Assays 292
Table 157: Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex
Biomarker Kits 294
Table 158: Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 295
Table 159: OriGene Technologies Enters Into Co-Development Agreement With Centre of
Excellence for Prevention of Organ Failure 296
Table 160: Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex
297
Table 161: IRIS International Enters Into Distribution Agreement With Alifax 298
Table 162: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 299
Table 163: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 301
Table 164: Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma
302
Table 165: RS Medical Enters Into Distribution Agreement With Harvest Technologies 303
Table 166: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International
304
Table 167: Sandia National Labs Plans To Enter Into Licensing Agreement For SpinDx, Medical


Diagnostic Tool 305
Table 168: HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For
Breast Cancer Marker Patent Portfolio 306
Table 169: Genisphere Enters Into Co-Development Agreement With Lankenau Institute for
Medical Research 307
Table 170: WaferGen Biosystems Enters Into Agreement With Integrated DNA Technologies
308
Table 171: Pacgen Enters Into Distribution Agreement With Arise Biotech For Pipettes 309
Table 172: BioView Enters Into Co-Development Agreement With ScreenCell For Circulating
Tumor Cell Analysis Technology 310
Table 173: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic
Test 311
Table 174: Fluxion Biosciences Enters Into Co-Development Agreement With Stanford
University School of Medicine 313
Table 175: Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment
Centers of America 314
Table 176: Phenomenome Discoveries Enters Into Licensing Agreement With Polymedco For
Cancer Diagnostic Test 315
Table 177: PlexPress Enters Into Technology Integration Agreement With Phalanx Biotech 316
Table 178: PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 317
Table 179: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis
Biomarkers For DNA-FISH Assays 319
Table 180: Stratos Enters Into Co- Development Agreement With nanoMR 320
Table 181: Guided Therapeutics Extends Licensing And Co-Development Agreement With
Konica Minolta 321
Table 182: CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test
322
Table 183: Berg Pharma Enters Into Co-Development Agreement With Parkinson's Institute 323
Table 184: Courtagen Life Sciences Enters Into Licensing Agreement With Scienion For
sciFlexArrayer Technology 324
Table 185: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For
AdenoPlus 325
Table 186: Leica Microsystems Enters Into Integration Agreement With Indica Labs 327
Table 187: Prolias Technologies Enters Into Licensing Agreement With Cornell University For
microRNA Diagnostic Portfolio 328
Table 188: Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab
For Septin9 Biomaker 329
Table 189: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis
330
Table 190: Asuragen Enters Into Licensing Agreement With Becton, Dickinson 332
Table 191: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4
POC Test 333


Table 192: KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 334
Table 193: Bruker Enters Into Research Agreement With Special Bacteriology Reference
Laboratory 335
Table 194: Bruker Enters Into Research Agreement With JMI Laboratories 337
Table 195: RayBiotech Enters Into Agreement With Oslo University Hospital And University of
Oslo 338
Table 196: Vela Diagnostics Enters Into Co-Development Agreement With Eppendorf 340
Table 197: One Lambda Enters Into Co-Marketing Agreement With CellTrend 341
Table 198: ImaginAb Extends Licensing Agreement With Bzl Biologics For Imaging Prostate
Specific Membrane Antigen 342
Table 199: Foundation Medicine Extends Co-Development Agreement With Novartis 343
Table 200: Affymetrix Enters Into Co-Development Agreement With Massachusetts General
Hospital For New Oncology Biomarker Tests 344
Table 201: Fluxion Bioscience Enters Into Technology Integration Agreement With Rubicon
Genomics 345
Table 202: Exosome Diagnostics Enters Into Technology Integration Agreement With Life
Technologies 346
Table 203: HTG Molecular Diagnostics Enters Into Co-Marketing Agreement With John Wayne
Cancer Institute 347
Table 204: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics
For ALK Cancer Biomarker 348
Table 205: Ventana Medical Enters Into Licensing Agreement With German Cancer Research
Center And University Hospital Heidelberg For BRAF V600E 349
Table 206: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems
351
Table 207: Radisens Diagnostics Enters Into Co-Development Agreement With Beckman
Coulter For HDR Detection Technology 353
Table 208: XDx Enters Into Agreement With LabCorp To Develop Lupus Flare Predictor Test
354
Table 209: Prosolia Enters Into Licensing Agreement With AB Sciex For ORNL Analytical
Technology 356
Table 210: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG
Marker 357
Table 211: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating
Tumor Cell Technology 359
Table 212: Exact Sciences Expands Licensing Agreement With Mayo Clinic 360
Table 213: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 361
Table 214: Dako Announces Licensing Agreement With Van Andel Research Institute For
Cancer Diagnostic Tool 362
Table 215: MicroFluidic Systems Enters Into Co-Development Agreement With University of
Nevada 363
Table 216: KineMed Enters Into Co-Development Agreement With CHDI Foundation 364


Table 217: ZyGem Enters Into Technology Integration Agreement With Quanta BioSciences 365
Table 218: Pressure BioSciences Enters Into Co-Development Agreement With Leap
Technologies, Vici Valco Instruments And Sage-N Research 366
Table 219: Islet Sciences Enters Into Licensing Agreement With Yale University For Early Beta
Cell Destruction and Diabetes Diagnostic 368
Table 220: Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma
369
Table 221: Applied Microarrays Enters Into Co-Development Agreement With Sensovation For
FlexiPlex Array System 370
Table 222: Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular
Diagnostic Products 371
Table 223: MetaStat Enters Into Licensing Agreement With Albert Einstein College of Medicine
For Metastatic Cell Technology Patents 372
Table 224: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For
LongRange PCR Kit 373
Table 225: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 374
Table 226: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 375
Table 227: Ezose Sciences Enters Into Co-Development Agreement With Hirosaki University
For New Cancer Biomarkers 377
Table 228: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 378
Table 229: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 379
Table 230: Miraculins Enters Into Co-Marketing Agreement With Pear Healthcare Solutions For
PreVu 380
Table 231: Abbott Enters Into Licensing Agreement With Stanford University For Prostate
Cancer Biomarkers 381
Table 232: Metabolon Enters Into Co-Development Agreement With Takeda Pharma 383
Table 233: Penn State Hershey Enters Into Co-Development Agreement With Serametrix 384
Table 234: Sysmex Extends Distribution Agreement With Roche 385
Table 235: Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement
With Ventana Medical Systems 387
Table 236: Rubicon Genomics Enters Into Technology Integration Agreement With Kreatech
Diagnostics 389
Table 237: NexDx Enters Into Licensing Agreement With University of California For
Epigenetic Biomarkers 390
Table 238: Elchrom Scientific Enters Into Technology Integration Agreement With Biotium 391
Table 239: RayBiotech Enters Into Co-Marketing Agreement With Innopsys 392
Table 240: BGN Technologies Enters Into Licensing Agreement With Lauren Sciences For V-
Smart Technology 393
Table 241: Stellar Biotechnologies Enters Into Option Licensing Agreement With University of
Guelph For Clostridium Difficile Technology 394


Table 242: Shimadzu Scientific Instruments Enters Into Joint Venture Agreement With
University of Texas 395
Table 243: Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development
Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 396
Table 244: Ridge Diagnostics Enters Into Licensing Agreement With Ameritox For MDDScore
397
Table 245: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 398
Table 246: LabCorp Enters Into Licensing Agreement With OPKO Health For Alzheimer's
Diagnostic Technology 400
Table 247: Accuray Enters Into Co-Development Agreement With University of Heidelberg 402
Table 248: HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-
aventis 403
Table 249: GenMark Diagnostics Enters Into Co-Development Agreement With Advanced
Liquid Logic For Integrated Diagnostic Platform 404
Table 250: PerkinElmer Enters Into Licensing Agreement With GenMark Diagnostics For
Microfluidics Patent Portfolio 406
Table 251: Bristol-Myers Squibb Enters Into Co-Development Agreement With Meso Scale 408
Table 252: Applied BioCode Enters Into Licensing Agreement With Douglas Scientific For
Barcoded Magnetic Beads Technology 409
Table 253: Molecular Response Enters Into Co-Marketing Agreement With Transparent 410
Table 254: IBM Enters Into Co-Development Agreement With Memorial Sloan-Kettering
Cancer Center 411
Table 255: QuantiScientifics Enters Into Co-Marketing Agreement With BioDot For A2
MicroArray System 412
Table 256: INOVA Diagnostics Enters Into Licensing Agreement With AmberGen And
Massachusetts General Hospital For Two Autoantigen Biomarkers 413
Table 257: Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For
LASEI DP-1000 415
Table 258: Devicor Medical Products Enters Into Co-Marketing Agreement With Carbon
Medical Technologies 416
Table 259: Diomics Enters Into Licensing Agreement With University of Arizona For DNA
Collection Technology 417
Table 260: Sage-N Research Enters Into Technology Integration Agreement With IO Informatics
418
Table 261: Mayo Medical Labs Enters Into Licensing Agreement With A&G Pharma For
Progranulin Blood Test 419
Table 262: Abbott Enters Into Co-Development Agreement With Genetics Lab For Molecular
Assay Development 420
Table 263: Avedro Enters Into Option Agreement With Cleveland Clinic To License Intellectual
Property Assets 421
Table 264: GE Global Research Enters Into Co-Development Agreement With InDevR 422
Table 265: Roche Enters Into Licensing Agreement With Life Technologies For PCR


Technology 423
Table 266: Vital Diagnostics Enters Into Distribution Agreement With Cardinal Health 424
Table 267: Dako Enters Into Co-Development Agreement With Amgen 425
Table 268: Iverson Genetic Diagnostics Enters Into Co-Development Agreement With
Vanderbilt University 426
Table 269: RedHill Biopharma Enters Into Co-Development Agreement With Quest Diagnostics
To Develop MAP Test For Crohn's Disease 427
Table 270: Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure Chemical
Industries 428
Table 271: Dolomite Centre Enters Into Co-Development Agreement With GigaGen 429
Table 272: Mitomics Enters Into Co-Marketing Agreement With LabMD For Prostate Core
Mitomic Test 430
Table 273: Fresh Start Private Management Enters Into Licensing Agreement With Glacier 431
Table 274: IRIS Sample Processing Enters Into Distribution Agreement With Fisher HealthCare
432
Table 275: Courtagen Life Sciences Enters Into Co-Development Agreement With Tetracore 433
Table 276: Quanterix, Beth Israel Deaconess And Forsyth Institute Enter Into Partnership To
Develop Tuberculosis Test 434
Table 277: Avesthagen Enters Into Co-Development Agreement With CosmosID 436
Table 278: Siemens Healthcare Diagnostics Enters Into Co-Development Agreement With ViiV
Healthcare 437
Table 279: Siemens Healthcare Diagnostics Enters Into Co-Development Agreement With
Tocagen 439
Table 280: Brooks Life Science Enters Into Licensing Agreement With The Scripps Research
Institute 441
Table 281: SDIX Enters Into Licensing Agreement With BD Diagnostic 443
Table 282: Thermo Fisher Scientific Enters Into Distribution Agreement With BellBrook Labs
444
Table 283: DuPont Enters Into Co-Development Agreement With OligoCo 445
Table 284: Genzyme Enters Into Co-Marketing Agreement With Veracyte 447
Table 285: Boulder Diagnostics Enters Into Licensing Agreement With Portland State University
448
Table 286: Ventana Medical Systems Enters Into Co-Development Agreement With Bayer
Pharma 449
Table 287: Pressure BioSciences Enters Into Co-Marketing Agreement With Digilab 451
Table 288: Agilent Technologies Enters Into Co-Development Agreement With Integrated
Diagnostics 453
Table 289: Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 454
Table 290: Ventana Medical Systems Enters Into Licensing Agreement With Cell Signaling
Technology 456
Table 291: Dako Enters Into Co-Development Agreement With Amgen 458
Table 292: Foundation Medicine Enters Into Co-Development Agreement With Sanofi For


Genetic Biomarkers And Potential Diagnostics 459
Table 293: University Of North Dakota Enters Into Licensing Agreement With NeoMatrix 460
Table 294: Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 461
Table 295: Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical
Systems 462
Table 296: ZyGEM Enters Into Co-Development Agreement With USAMRIID 464
Table 297: AEterna Zentaris Enters Into Co-Development Agreement With Ventana Medical
Systems 465
Table 298: Boulder Diagnostics Enters Into Licensing Agreement With RUNMC 467
Table 299: HistoRx Enters Into Licensing Agreement With Yale University 4681.2 List of
Figures
Figure 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m), USD Constant, 2004-
2018 44
Figure 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-
2018 45
Figure 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2004-2018 47
Figure 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Historic,
2004-2011 49
Figure 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 51
Figure 6: In Vitro Diagnostics, North America, Company share (%), 2011 53
Figure 7: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018
55
Figure 8: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic,
2004-2011 57
Figure 9: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 59
Figure 10: In Vitro Diagnostics, United States, Company Share (%), 2011 65
Figure 11: Clinical Chemistry, United States, Company Share (%), 2011 67
Figure 12: Genetic Testing, United States, Company Share (%), 2011 68
Figure 13: Haematology, United States, Company Share (%), 2011 70
Figure 14: Immuno Chemistry, United States, Company Share (%), 2011 72
Figure 15: Infectious Immunology, United States, Company Share (%), 2011 74
Figure 16: Microbiology Culture, United States, Company Share (%), 2011 76
Figure 17: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 78
Figure 18: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Historic, 2004-
2011 80
Figure 19: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 82
Figure 20: In Vitro Diagnostics, Canada, Company Share (%), 2011 88
Figure 21: Clinical Chemistry, Canada, Company Share (%), 2011 90
Figure 22: Genetic Testing, Canada, Company Share (%), 2011 92


Figure 23: Haematology, Canada, Company Share (%), 2011 94
Figure 24: Histology And Cytology, Canada, Company Share (%), 2011 96
Figure 25: Immuno Chemistry, Canada, Company Share (%), 2011 98
Figure 26: Infectious Immunology, Canada, Company Share (%), 2011 100
Figure 27: Microbiology Culture, Canada, Company Share (%), 2011 102
Figure 28: Siemens Healthcare, Company Share (%), North America In Vitro Diagnostics
Market, 2011 104
Figure 29: Abbott Laboratories, Company Share (%),North America In Vitro Diagnostics
Market, 2011 105
Figure 30: F. Hoffmann-La Roche Ltd., Company Share (%),North America In Vitro Diagnostics
Market, 2011 106
Figure 31: F. Hoffmann-La Roche Ltd., Company Share (%),North America In Vitro Diagnostics
Market, 2011 107
Figure 32: Ortho-Clinical Diagnostics Inc., Company Share (%),North America In Vitro
Diagnostics Market, 2011 108
Figure 33: Alere Inc, Company Share (%),North America In Vitro Diagnostics Market, 2011 109

BUY NOW

North america in vitro diagnostics market outlook to 2018

Recomendados

Recomendados

Más contenido relacionado

Destacado

Destacado (20)

North america in vitro diagnostics market outlook to 2018